RE:RE:RE:Anyone want to chime in on whether the soon to 4050 likely coming online in 2019, in the earliest of indications. Anything past that (ie new indications) just means more money on more trials..
IPF results.. with the trial being done again, it won't be much of a push up. Yes proof of concept, but not enough yet. Nevermind that we're behind the curve in regards to what we know vs. what big money knows.
The difference I see this time is the premarket wasn't as crazy. It used to be +0.50 premarket all hype on news days, open even, and then end up in the red.
I'm not a professional by any means.. but if we're trying to keep as much of it in house regarding licensing and production. what deal is left to be had? It's an honest question for anyone who can answer. supply? distribution? granted pretty lucrative but we need to have an approved product. why would anyone touch it, if it isn't approved.
Plasmingen coming online this summer to a seemingly decent market, will be a catalyst for sure but how much? We still don't have any clue on the real numbers or how the off label use will play into it, because it's not approved yet and no one knows about us.
I don't think the last of the 1.50's.